The drug is an anti-platelet agent to decrease clumping of platelets to form blood clots. By reducing blood clots this lowers the risk of a heart attack or stroke. It carries a boxed warning as it does thin blood. It is not for patients who have had a stroke. For those who have peripheral arterial disease this will lower the risk of a heart attack and stroke. BD
The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous
heart attack or blockages in the arteries to the legs.
Zontivity is the first in a new class of drug, called a protease-activated receptor-1 (PAR-1) antagonist. It is an anti-platelet agent, designed to decrease the tendency of platelets to clump together to form a blood clot. By decreasing the formation of blood clots, Zontivity decreases the risk of heart attack and stroke.
Like other drugs that inhibit blood clotting, Zontivity increases the risk of bleeding, including life-threatening and fatal bleeding. Bleeding is the most commonly reported adverse reaction in people taking Zontivity. The drug’s prescribing information (label) includes a Boxed Warning to alert health care professionals about this risk.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm
0 comments :
Post a Comment